{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:47:18Z","timestamp":1762508838033},"reference-count":90,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,23]]},"DOI":"10.7759\/cureus.27180","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T18:57:57Z","timestamp":1658602677000},"source":"Crossref","is-referenced-by-count":5,"title":["Topical Biological Agents as Adjuncts to Improve Wound Healing in Chronic Diabetic Wounds: A Systematic Review of Clinical Evidence and Future Directions"],"prefix":"10.7759","author":[{"given":"Andrew Yew Wei","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard Soon Yang","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainsley Ryan Yan Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron Shengting","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathiyamoorthy","family":"Selvarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish  R","family":"Lakshminarasappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook Muay","family":"Tay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"National Diabetes Statistics Report 2020. Estimates of Diabetes and Its Burden in the United States","author":"US Department of Health and Human Services","year":"2020","unstructured":"US Department of Health and Human Services. National Diabetes Statistics Report 2020. Estimates of Diabetes and Its Burden in the United States. CDC, Atlanta, Georgia; 2020."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20080020","article-title":"Epidemiology of diabetes and diabetes-related complications","volume":"88","author":"Deshpande AD","year":"2008","unstructured":"Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008, 88:1254-64. 10.2522\/ptj.20080020","journal-title":"Phys Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2248","article-title":"Expert opinion on the management of infections in the diabetic foot","volume":"28 Suppl 1","author":"Lipsky BA","year":"2012","unstructured":"Lipsky BA, Peters EJ, Senneville E, et al.. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab Res Rev. 2012, 28 Suppl 1:163-78. 10.1002\/dmrr.2248","journal-title":"Diabetes Metab Res Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.2.217","article-title":"Preventing foot ulcers in patients with diabetes","volume":"293","author":"Singh N","year":"2005","unstructured":"Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005, 293:217-28. 10.1001\/jama.293.2.217","journal-title":"JAMA"},{"key":"ref5","article-title":"The impact of diabetic foot ulcer pain on patient quality of life","volume":"7","author":"Bradbury S","year":"2011","unstructured":"Bradbury S, Price P. The impact of diabetic foot ulcer pain on patient quality of life. Wounds. 2011, 7:","journal-title":"Wounds"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1990.tb01300.x","article-title":"Employment problems and diabetes","volume":"7","author":"Robinson N","year":"1990","unstructured":"Robinson N, Yateman NA, Protopapa LE, Bush L. Employment problems and diabetes. Diabet Med. 1990, 7:16-22. 10.1111\/j.1464-5491.1990.tb01300.x","journal-title":"Diabet Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20164741","article-title":"Wound healing - a literature review","volume":"91","author":"Gonzalez AC","year":"2016","unstructured":"Gonzalez AC, Costa TF, Andrade ZA, Medrado AR. Wound healing - a literature review. An Bras Dermatol. 2016, 91:614-20. 10.1590\/abd1806-4841.20164741","journal-title":"An Bras Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9021","article-title":"Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists","volume":"31","author":"Boulton AJ","year":"2008","unstructured":"Boulton AJ, Armstrong DG, Albert SF, et al.. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008, 31:1679-85. 10.2337\/dc08-9021","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/17482631.2021.1945206","article-title":"Qualitative exploration into reasons for delay in seeking medical help with diabetic foot problems","volume":"16","author":"Ogunlana MO","year":"2021","unstructured":"Ogunlana MO, Govender P, Oyewole OO, Odole AC, Falola JL, Adesina OF, Akindipe JA. Qualitative exploration into reasons for delay in seeking medical help with diabetic foot problems. Int J Qual Stud Health Well-being. 2021, 16:1945206. 10.1080\/17482631.2021.1945206","journal-title":"Int J Qual Stud Health Well-being"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4037\/15597768-1990-3013","article-title":"The influence of tissue oxygen and perfusion on wound healing","volume":"1","author":"Whitney JD","year":"1990","unstructured":"Whitney JD. The influence of tissue oxygen and perfusion on wound healing. AACN Clin Issues Crit Care Nurs. 1990, 1:578-84. 10.4037\/15597768-1990-3013","journal-title":"AACN Clin Issues Crit Care Nurs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker PM","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al.. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-207. 10.1056\/NEJMoa0807646","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.97.5.425","article-title":"Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease","volume":"97","author":"Ridker PM","year":"1998","unstructured":"Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998, 97:425-8. 10.1161\/01.cir.97.5.425","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht149","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I","volume":"34","author":"Paneni F","year":"2013","unstructured":"Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013, 34:2436-43. 10.1093\/eurheartj\/eht149","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091257.27563.32","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I","volume":"108","author":"Creager MA","year":"2003","unstructured":"Creager MA, L\u00fcscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003, 108:1527-32. 10.1161\/01.CIR.0000091257.27563.32","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.88.2.e14","article-title":"Mechanisms underlying endothelial dysfunction in diabetes mellitus","volume":"88","author":"Hink U","year":"2001","unstructured":"Hink U, Li H, Mollnau H, et al.. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001, 88:E14-22. 10.1161\/01.res.88.2.e14","journal-title":"Circ Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2012.03.003","article-title":"Nitrite and nitric oxide metabolism in peripheral artery disease","volume":"26","author":"Allen JD","year":"2012","unstructured":"Allen JD, Giordano T, Kevil CG. Nitrite and nitric oxide metabolism in peripheral artery disease. Nitric Oxide. 2012, 26:217-22. 10.1016\/j.niox.2012.03.003","journal-title":"Nitric Oxide"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.217117","article-title":"Activation of protein kinase C isoforms and its impact on diabetic complications","volume":"106","author":"Geraldes P","year":"2010","unstructured":"Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010, 106:1319-31. 10.1161\/CIRCRESAHA.110.217117","journal-title":"Circ Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2007.01824.x","article-title":"Diabetes mellitus as a prothrombotic condition","volume":"262","author":"Grant PJ","year":"2007","unstructured":"Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007, 262:157-72. 10.1111\/j.1365-2796.2007.01824.x","journal-title":"J Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.11.052","article-title":"Diabetes mellitus and thrombosis","volume":"129","author":"Vazzana N","year":"2012","unstructured":"Vazzana N, Ranalli P, Cuccurullo C, Dav\u00ec G. Diabetes mellitus and thrombosis. Thromb Res. 2012, 129:371-7. 10.1016\/j.thromres.2011.11.052","journal-title":"Thromb Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32169","article-title":"Cellular and molecular basis of wound healing in diabetes","volume":"117","author":"Brem H","year":"2007","unstructured":"Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007, 117:1219-22. 10.1172\/JCI32169","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7330.160","article-title":"Science, medicine and the future: healing chronic wounds","volume":"324","author":"Harding KG","year":"2002","unstructured":"Harding KG, Morris HL, Patel GK. Science, medicine and the future: healing chronic wounds. BMJ. 2002, 324:160-3. 10.1136\/bmj.324.7330.160","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12391","article-title":"WHS guidelines update: diabetic foot ulcer treatment guidelines","volume":"24","author":"Lavery LA","year":"2016","unstructured":"Lavery LA, Davis KE, Berriman SJ, et al.. WHS guidelines update: diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016, 24:112-26. 10.1111\/wrr.12391","journal-title":"Wound Repair Regen"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky BA","year":"2012","unstructured":"Lipsky BA, Berendt AR, Cornia PB, et al.. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012, 54:e132-73. 10.1093\/cid\/cis346","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-0940-0","article-title":"Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study","volume":"51","author":"Prompers L","year":"2008","unstructured":"Prompers L, Schaper N, Apelqvist J, et al.. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008, 51:747-55. 10.1007\/s00125-008-0940-0","journal-title":"Diabetologia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240450403","article-title":"Therapeutic application of growth factors","volume":"45","author":"Pierce GF","year":"1991","unstructured":"Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Therapeutic application of growth factors. J Cell Biochem. 1991, 45:319-65. 10.1002\/jcb.240450403","journal-title":"J Cell Biochem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009100","article-title":"Structural and functional properties of platelet-derived growth factor and stem cell factor receptors","volume":"5","author":"Heldin CH","year":"2013","unstructured":"Heldin CH, Lennartsson J. Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb Perspect Biol. 2013, 5:a009100. 10.1101\/cshperspect.a009100","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref27","article-title":"Chapter 9 - molecular determinants of cardiac neovascularization","author":"Mar\u00edn-Garc\u00eda J","year":"2014","unstructured":"Mar\u00edn-Garc\u00eda J. Chapter 9 - molecular determinants of cardiac neovascularization. Post-Genomic Cardiology (Second Edition). J Mar\u00edn-Garc\u00eda (ed): Elsevier, Amsterdam, Netherlands; 2014."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00117","article-title":"Use of human umbilical cord and its byproducts in tissue regeneration","volume":"8","author":"Velarde F","year":"2020","unstructured":"Velarde F, Casta\u00f1eda V, Morales E, et al.. Use of human umbilical cord and its byproducts in tissue regeneration. Front Bioeng Biotechnol. 2020, 8:117. 10.3389\/fbioe.2020.00117","journal-title":"Front Bioeng Biotechnol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00016","article-title":"Therapeutic potential of Wharton\u2019s Jelly mesenchymal stem cells for diabetes: achievements and challenges","volume":"8","author":"Kamal MM","year":"2020","unstructured":"Kamal MM, Kassem DH. Therapeutic potential of Wharton\u2019s Jelly mesenchymal stem cells for diabetes: achievements and challenges. Front Cell Dev Biol. 2020, 8:16. 10.3389\/fcell.2020.00016","journal-title":"Front Cell Dev Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-475X.2008.00449.x","article-title":"FGF-10 and specific structural elements of dermatan sulfate size and sulfation promote maximal keratinocyte migration and cellular proliferation","volume":"17","author":"Radek KA","year":"2009","unstructured":"Radek KA, Taylor KR, Gallo RL. FGF-10 and specific structural elements of dermatan sulfate size and sulfation promote maximal keratinocyte migration and cellular proliferation. Wound Repair Regen. 2009, 17:118-26. 10.1111\/j.1524-475X.2008.00449.x","journal-title":"Wound Repair Regen"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.2.357","article-title":"Purification and characterization of acidic fibroblast growth factor from bovine brain","volume":"81","author":"Thomas KA","year":"1984","unstructured":"Thomas KA, Rios-Candelore M, Fitzpatrick S. Purification and characterization of acidic fibroblast growth factor from bovine brain. Proc Natl Acad Sci U S A. 1984, 81:357-61. 10.1073\/pnas.81.2.357","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240210302","article-title":"Purification and partial characterization of bovine pituitary fibroblast growth factor","volume":"21","author":"Lemmon SK","year":"1983","unstructured":"Lemmon SK, Bradshaw RA. Purification and partial characterization of bovine pituitary fibroblast growth factor. J Cell Biochem. 1983, 21:195-208. 10.1002\/jcb.240210302","journal-title":"J Cell Biochem"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2008.04.023","article-title":"The role of vascular endothelial growth factor in wound healing","volume":"153","author":"Bao P","year":"2009","unstructured":"Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009, 153:347-58. 10.1016\/j.jss.2008.04.023","journal-title":"J Surg Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet P","year":"2011","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011, 473:298-307. 10.1038\/nature10144","journal-title":"Nature"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-653","article-title":"Angiogenesis in health and disease","volume":"9","author":"Carmeliet P","year":"2003","unstructured":"Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003, 9:653-60. 10.1038\/nm0603-653","journal-title":"Nat Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.fsc.2019.03.005","article-title":"The benefits of platelet-rich fibrin","volume":"27","author":"Karimi K","year":"2019","unstructured":"Karimi K, Rockwell H. The benefits of platelet-rich fibrin. Facial Plast Surg Clin North Am. 2019, 27:331-40. 10.1016\/j.fsc.2019.03.005","journal-title":"Facial Plast Surg Clin North Am"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4103\/2231-0746.83158","article-title":"Platelet-rich fibrin: a second generation platelet concentrate and a new friend of oral and maxillofacial surgeons","volume":"1","author":"Saluja H","year":"2011","unstructured":"Saluja H, Dehane V, Mahindra U. Platelet-rich fibrin: a second generation platelet concentrate and a new friend of oral and maxillofacial surgeons. Ann Maxillofac Surg. 2011, 1:53-7. 10.4103\/2231-0746.83158","journal-title":"Ann Maxillofac Surg"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.92602","article-title":"Platelet rich fibrin (PRF) application in oral surgery","author":"Saglanmak A","year":"2020","unstructured":"Saglanmak A, Cinar C, Gultekin A. Platelet rich fibrin (PRF) application in oral surgery. Platelets. IntechOpen, London, UK; 2020. 10.5772\/intechopen.92602"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-018-1087-0","article-title":"Clinical application of platelet-rich fibrin in plastic and reconstructive surgery: a systematic review","volume":"42","author":"Yu P","year":"2018","unstructured":"Yu P, Zhai Z, Jin X, Yang X, Qi Z. Clinical application of platelet-rich fibrin in plastic and reconstructive surgery: a systematic review. Aesthetic Plast Surg. 2018, 42:511-9. 10.1007\/s00266-018-1087-0","journal-title":"Aesthetic Plast Surg"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116130","article-title":"Epidermal growth factor receptor distribution in burn wounds. Implications for growth factor-mediated repair","volume":"90","author":"Wenczak BA","year":"1992","unstructured":"Wenczak BA, Lynch JB, Nanney LB. Epidermal growth factor receptor distribution in burn wounds. Implications for growth factor-mediated repair. J Clin Invest. 1992, 90:2392-401. 10.1172\/JCI116130","journal-title":"J Clin Invest"},{"key":"ref41","unstructured":"Epidermal growth factor. (2007). https.\/\/embryo.asu.edu\/pages\/epidermal-growth-factor."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/s1479-666x(08)80114-x","article-title":"Epidermal growth factor therapy and wound healing \u2014 past, present and future perspectives","volume":"6","author":"Hardwicke J","year":"2008","unstructured":"Hardwicke J, Schmaljohann D, Boyce D, Thomas D. Epidermal growth factor therapy and wound healing \u2014 past, present and future perspectives. Surgeon. 2008, 6:172-7. 10.1016\/s1479-666x(08)80114-x","journal-title":"Surgeon"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.1016\/S0197-2456(99)00026-4","article-title":"Assessing the quality of randomized trials: reliability of the Jadad scale","volume":"20","author":"Clark HD","year":"1999","unstructured":"Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, Fergusson D. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999, 20:448-52.","journal-title":"Control Clin Trials"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.5.822","article-title":"Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study","volume":"21","author":"Wieman TJ","year":"1998","unstructured":"Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998, 21:822-7. 10.2337\/diacare.21.5.822","journal-title":"Diabetes Care"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000222526.21512.4c","article-title":"Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers","volume":"117","author":"Steed DL","year":"2006","unstructured":"Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg. 2006, 117:143S-149S; discussion 150S-151S. 10.1097\/01.prs.0000222526.21512.4c","journal-title":"Plast Reconstr Surg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/00129334-200506000-00012","article-title":"Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers","volume":"18","author":"Niezgoda JA","year":"2005","unstructured":"Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005, 18:258-66. 10.1097\/00129334-200506000-00012","journal-title":"Adv Skin Wound Care"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.7547\/1000155","article-title":"Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis","volume":"100","author":"Landsman A","year":"2010","unstructured":"Landsman A, Agnew P, Parish L, Joseph R, Galiano RD. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis. J Am Podiatr Med Assoc. 2010, 100:155-60. 10.7547\/1000155","journal-title":"J Am Podiatr Med Assoc"},{"key":"ref48","article-title":"Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial","volume":"27","author":"Ma C","year":"2015","unstructured":"Ma C, Hernandez MA, Kirkpatrick VE, Liang LJ, Nouvong AL, Gordon II. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial. Wounds. 2015, 27:83-91.","journal-title":"Wounds"},{"key":"ref49","article-title":"Foot care education and platelet derived growth factor on wound healing in foot ulcers among adults","volume":"6","author":"D'Souza MS","year":"2016","unstructured":"D'Souza MS, D'Souza J, Karkada SN. Foot care education and platelet derived growth factor on wound healing in foot ulcers among adults. Int J Nutr Pharmacol Neurol Dis. 2016, 6:111-8.","journal-title":"Int J Nutr Pharmacol Neurol Dis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002371","article-title":"Placental membrane provides improved healing efficacy and lower cost versus a tissue-engineered human skin in the treatment of diabetic foot ulcerations","volume":"7","author":"Glat P","year":"2019","unstructured":"Glat P, Orgill DP, Galiano R, et al.. Placental membrane provides improved healing efficacy and lower cost versus a tissue-engineered human skin in the treatment of diabetic foot ulcerations. Plast Reconstr Surg Glob Open. 2019, 7:e2371. 10.1097\/GOX.0000000000002371","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0142","article-title":"A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers","volume":"9","author":"Serena TE","year":"2020","unstructured":"Serena TE, Yaakov R, Moore S, et al.. A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers. J Comp Eff Res. 2020, 9:23-34. 10.2217\/cer-2019-0142","journal-title":"J Comp Eff Res"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12395","article-title":"A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion\/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers","volume":"12","author":"Zelen CM","year":"2015","unstructured":"Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion\/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015, 12:724-32. 10.1111\/iwj.12395","journal-title":"Int Wound J"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12954","article-title":"Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: a prospective, randomised, multi-centre clinical trial in 80 patients","volume":"15","author":"DiDomenico LA","year":"2018","unstructured":"DiDomenico LA, Orgill DP, Galiano RD, et al.. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: a prospective, randomised, multi-centre clinical trial in 80 patients. Int Wound J. 2018, 15:950-7. 10.1111\/iwj.12954","journal-title":"Int Wound J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12976","article-title":"A confirmatory study on the efficacy of dehydrated human amnion\/chorion membrane dHACM allograft in the management of diabetic foot ulcers: a prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics","volume":"16","author":"Tettelbach W","year":"2019","unstructured":"Tettelbach W, Cazzell S, Reyzelman AM, Sigal F, Caporusso JM, Agnew PS. A confirmatory study on the efficacy of dehydrated human amnion\/chorion membrane dHACM allograft in the management of diabetic foot ulcers: a prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J. 2019, 16:19-29. 10.1111\/iwj.12976","journal-title":"Int Wound J"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.13001","article-title":"A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers","volume":"16","author":"Tettelbach W","year":"2019","unstructured":"Tettelbach W, Cazzell S, Sigal F, Caporusso JM, Agnew PS, Hanft J, Dove C. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. Int Wound J. 2019, 16:122-30. 10.1111\/iwj.13001","journal-title":"Int Wound J"},{"key":"ref56","article-title":"A prospective, randomized, multicenter, controlled evaluation of the use of dehydrated amniotic membrane allograft compared to standard of care for the closure of chronic diabetic foot ulcer","volume":"28","author":"Snyder RJ","year":"2016","unstructured":"Snyder RJ, Shimozaki K, Tallis A, et al.. A prospective, randomized, multicenter, controlled evaluation of the use of dehydrated amniotic membrane allograft compared to standard of care for the closure of chronic diabetic foot ulcer. Wounds. 2016, 28:70-7.","journal-title":"Wounds"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2009.0750","article-title":"Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer","volume":"19","author":"UC H","year":"2009","unstructured":"UC H, IG A, UR K, et al.. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 2009, 19:461-8. 10.1684\/ejd.2009.0750","journal-title":"Eur J Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tea.2012.0634","article-title":"Novel collagen\/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers","volume":"19","author":"Morimoto N","year":"2013","unstructured":"Morimoto N, Yoshimura K, Niimi M, et al.. Novel collagen\/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers. Tissue Eng Part A. 2013, 19:1931-40. 10.1089\/ten.tea.2012.0634","journal-title":"Tissue Eng Part A"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.15.11.1598","article-title":"Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo","volume":"15","author":"Steed DL","year":"1992","unstructured":"Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care. 1992, 15:1598-604. 10.2337\/diacare.15.11.1598","journal-title":"Diabetes Care"},{"key":"ref60","article-title":"Concentrated growth factors (CGF) for the treatment of vascular non-healing ulcers: preliminary data of a randomized multicenter prospective study","volume":"23","author":"Santoro WI","year":"2018","unstructured":"Santoro WI, Farina E, Giugliano G, Farina MA. Concentrated growth factors (CGF) for the treatment of vascular non-healing ulcers: preliminary data of a randomized multicenter prospective study. Vascular Medicine. 2018, 23:303.","journal-title":"Vascular Medicine"},{"key":"ref61","unstructured":"The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe. The TRANS-North Study. (2010). https.\/\/clinicaltrials.gov\/ct2\/show\/NCT01217476."},{"key":"ref62","unstructured":"The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe the TRANS-South Study. (2010). https.\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01217463."},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201907_18345","article-title":"Observation of curative effect of recombinant human basic fibroblast growth factor combined with compound polymyxin B ointment and local application of insulin on wound healing of deep second-degree burn in diabetes mellitus: a randomized study","volume":"23","author":"Zhang JB","year":"2019","unstructured":"Zhang JB, Li H, Zhang L, Wang JL. Observation of curative effect of recombinant human basic fibroblast growth factor combined with compound polymyxin B ointment and local application of insulin on wound healing of deep second-degree burn in diabetes mellitus: a randomized study. Eur Rev Med Pharmacol Sci. 2019, 23:5987-93. 10.26355\/eurrev_201907_18345","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.1.64","article-title":"Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study","volume":"18","author":"Richard JL","year":"1995","unstructured":"Richard JL, Parer-Richard C, Daures JP, et al.. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care. 1995, 18:64-9. 10.2337\/diacare.18.1.64","journal-title":"Diabetes Care"},{"key":"ref65","article-title":"Healing of chronic cutaneous wounds by topical treatment with basic fibroblast growth factor","volume":"115","author":"Fu X","year":"2002","unstructured":"Fu X, Shen Z, Guo Z, Zhang M, Sheng Z. Healing of chronic cutaneous wounds by topical treatment with basic fibroblast growth factor. Chin Med J (Engl). 2002, 115:331-5.","journal-title":"Chin Med J (Engl)"},{"key":"ref66","article-title":"Treatment of diabetic foot disease by recombinant bovine basic fibroblast growth factor: randomized controlled observation on the therapeutic effect","volume":"8","author":"FF Zheng H\u2010T","year":"2019","unstructured":"FF Zheng H\u2010T, Chen W, Liu L, Feng X\u2010L, Xu J. Treatment of diabetic foot disease by recombinant bovine basic fibroblast growth factor: randomized controlled observation on the therapeutic effect. Chinese Journal of Clinical Rehabilitation [Article in Chinese]. 2019, 8:6564.","journal-title":"Chinese Journal of Clinical Rehabilitation [Article in Chinese]"},{"key":"ref67","article-title":"Prosthetic effect of recombinant human epidermal growth factor combined with basic fibroblast growth factor on diabetic wound healing [Article in Chinese]","volume":"10","author":"Song ZQ","year":"2006","unstructured":"Song ZQ, Wang RX. Prosthetic effect of recombinant human epidermal growth factor combined with basic fibroblast growth factor on diabetic wound healing [Article in Chinese]. Chinese Journal of Clinical Rehabilitation. 2006, 10:53-5.","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"key":"ref68","article-title":"Effect of autologous platelet-rich gel on the treatment of diabetic foot ulcers","volume":"37","author":"Liu G\u2010Y","year":"2016","unstructured":"Liu G\u2010Y, Sun Y, Wang M\u2010Z, Gao J, Gou J [Article in Chinese]. Effect of autologous platelet-rich gel on the treatment of diabetic foot ulcers. Journal of Xi'an Jiaotong University. 2016, 37:264-7.","journal-title":"Journal of Xi'an Jiaotong University"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6131","article-title":"Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds","volume":"15","author":"Xu J","year":"2018","unstructured":"Xu J, Min D, Guo G, Liao X, Fu Z. Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds. Exp Ther Med. 2018, 15:5365-70. 10.3892\/etm.2018.6131","journal-title":"Exp Ther Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2008.17.1.27917","article-title":"Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers","volume":"17","author":"Hanft JR","year":"2008","unstructured":"Hanft JR, Pollak RA, Barbul A, et al.. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care. 2008, 17:30-2, 34-7. 10.12968\/jowc.2008.17.1.27917","journal-title":"J Wound Care"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12294","article-title":"Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: a prospective, randomized clinical trial","volume":"23","author":"Li L","year":"2015","unstructured":"Li L, Chen D, Wang C, et al.. Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: a prospective, randomized clinical trial. Wound Repair Regen. 2015, 23:495-505. 10.1111\/wrr.12294","journal-title":"Wound Repair Regen"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-05316-0","article-title":"Randomized controlled trial on autologous platelet-rich plasma versus saline dressing in treatment of non-healing diabetic foot ulcers","volume":"44","author":"Elsaid A","year":"2020","unstructured":"Elsaid A, El-Said M, Emile S, Youssef M, Khafagy W, Elshobaky A. Randomized controlled trial on autologous platelet-rich plasma versus saline dressing in treatment of non-healing diabetic foot ulcers. World J Surg. 2020, 44:1294-301. 10.1007\/s00268-019-05316-0","journal-title":"World J Surg"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2019.28.1.15","article-title":"Use of platelet-rich plasma and platelet-derived patches to treat chronic wounds","volume":"28","author":"Tsai HC","year":"2019","unstructured":"Tsai HC, Lehman CW, Chen CM. Use of platelet-rich plasma and platelet-derived patches to treat chronic wounds. J Wound Care. 2019, 28:15-21. 10.12968\/jowc.2019.28.1.15","journal-title":"J Wound Care"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2016.04.023","article-title":"Platelet-rich plasma for the treatment of clean diabetic foot ulcers","volume":"38","author":"Ahmed M","year":"2017","unstructured":"Ahmed M, Reffat SA, Hassan A, Eskander F. Platelet-rich plasma for the treatment of clean diabetic foot ulcers. Ann Vasc Surg. 2017, 38:206-11. 10.1016\/j.avsg.2016.04.023","journal-title":"Ann Vasc Surg"},{"key":"ref75","article-title":"A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers","volume":"52","author":"Driver VR","year":"2006","unstructured":"Driver VR, Hanft J, Fylling CP, Beriou JM. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006, 52:68-70, 72, 74 passim.","journal-title":"Ostomy Wound Manage"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/s0939-4753(04)80029-2","article-title":"A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers","volume":"14","author":"Saldalamacchia G","year":"2004","unstructured":"Saldalamacchia G, Lapice E, Cuomo V, De Feo E, D'Agostino E, Rivellese AA, Vaccaro O. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutr Metab Cardiovasc Dis. 2004, 14:395-6. 10.1016\/s0939-4753(04)80029-2","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2007.03.006","article-title":"Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial","volume":"21","author":"Kakagia DD","year":"2007","unstructured":"Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, Tripsiannis G, Manolas C. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. J Diabetes Complications. 2007, 21:387-91. 10.1016\/j.jdiacomp.2007.03.006","journal-title":"J Diabetes Complications"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.6.1856","article-title":"Human epidermal growth factor enhances healing of diabetic foot ulcers","volume":"26","author":"Tsang MW","year":"2003","unstructured":"Tsang MW, Wong WK, Hung CS, et al.. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003, 26:1856-61. 10.2337\/diacare.26.6.1856","journal-title":"Diabetes Care"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.2217\/14750708.2.5.759","article-title":"Efficacy of topical epidermal growth factor in healing diabetic foot ulcers","volume":"2","author":"Afshari M","year":"2005","unstructured":"Afshari M, Larijani B, Fadayee M, et al.. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy. 2005, 2:759-65. 10.2217\/14750708.2.5.759","journal-title":"Therapy"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1177\/1534734619892791","article-title":"Efficacy of recombinant human epidermal growth factor (Regen-D 150) in healing diabetic foot ulcers: a hospital-based randomized controlled trial","volume":"19","author":"Viswanathan V","year":"2020","unstructured":"Viswanathan V, Juttada U, Babu M. Efficacy of recombinant human epidermal growth factor (Regen-D 150) in healing diabetic foot ulcers: a hospital-based randomized controlled trial. Int J Low Extrem Wounds. 2020, 19:158-64. 10.1177\/1534734619892791","journal-title":"Int J Low Extrem Wounds"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12187","article-title":"Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial","volume":"22","author":"Gomez-Villa R","year":"2014","unstructured":"Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al.. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial. Wound Repair Regen. 2014, 22:497-503. 10.1111\/wrr.12187","journal-title":"Wound Repair Regen"},{"key":"ref82","article-title":"Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's grade 1 and 2 diabetic foot ulcers: comparative analysis of 50 patients","volume":"5","author":"Singla S","year":"2014","unstructured":"Singla S, Garg R, Kumar A, Gill C. Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's grade 1 and 2 diabetic foot ulcers: comparative analysis of 50 patients. J Nat Sci Biol Med. 2014, 5:273-7.","journal-title":"J Nat Sci Biol Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2009.00641.x","article-title":"Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study","volume":"6","author":"Fern\u00e1ndez-Montequ\u00edn JI","year":"2009","unstructured":"Fern\u00e1ndez-Montequ\u00edn JI, Valenzuela-Silva CM, D\u00edaz OG, et al.. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009, 6:432-43. 10.1111\/j.1742-481X.2009.00641.x","journal-title":"Int Wound J"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2018.27.9.550","article-title":"Role of platelet-rich plasma in healing diabetic foot ulcers: a prospective study","volume":"27","author":"Singh SP","year":"2018","unstructured":"Singh SP, Kumar V, Pandey A, Pandey P, Gupta V, Verma R. Role of platelet-rich plasma in healing diabetic foot ulcers: a prospective study. J Wound Care. 2018, 27:550-6. 10.12968\/jowc.2018.27.9.550","journal-title":"J Wound Care"},{"key":"ref85","unstructured":"Amniox announces initiation for first of two Phase 3 clinical trials of cryopreserved umbilical cord TTAX01 allograft to treat complex Wagner grade 3-4 diabetic foot ulcers. (2020). https.\/\/biotissue.com\/news\/amniox-announces-initiation-for-first-of-two-phase-3-clinical-trials-of-cryopreserved-umbi...."},{"key":"ref86","unstructured":"A Phase 3 clinical trial to assess the effectiveness of BioChaperone PDGF-BB in the treatment of chronic diabetic foot ulcer. (2014). https.\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02236793."},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8080276","article-title":"Vivostat Platelet-Rich Fibrin\u00ae for complicated or chronic wounds\u2014a pilot study","volume":"8","author":"Bayer A","year":"2020","unstructured":"Bayer A, H\u00f6ntsch G, Kaschwich M, et al.. Vivostat Platelet-Rich Fibrin\u00ae for complicated or chronic wounds\u2014a pilot study. Biomedicines. 2020, 8:10.3390\/biomedicines8080276","journal-title":"Biomedicines"},{"key":"ref88","unstructured":"Evaluation of the effect of Vivostat Platelet Rich Fibrin (PRF) in the treatment of diabetic foot ulcers. (2008). https.\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00770939."},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12754","article-title":"An open-label trial of cryopreserved human umbilical cord in the treatment of complex diabetic foot ulcers complicated by osteomyelitis","volume":"27","author":"Marston WA","year":"2019","unstructured":"Marston WA, Lantis JC 2nd, Wu SC, et al.. An open-label trial of cryopreserved human umbilical cord in the treatment of complex diabetic foot ulcers complicated by osteomyelitis. Wound Repair Regen. 2019, 27:680-6. 10.1111\/wrr.12754","journal-title":"Wound Repair Regen"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0536-8","article-title":"Reasonable glycemic control would help wound healing during the treatment of diabetic foot ulcers","volume":"10","author":"Xiang J","year":"2019","unstructured":"Xiang J, Wang S, He Y, Xu L, Zhang S, Tang Z. Reasonable glycemic control would help wound healing during the treatment of diabetic foot ulcers. Diabetes Ther. 2019, 10:95-105. 10.1007\/s13300-018-0536-8","journal-title":"Diabetes Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/82220-topical-biological-agents-as-adjuncts-to-improve-wound-healing-in-chronic-diabetic-wounds-a-systematic-review-of-clinical-evidence-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:23Z","timestamp":1707507623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/82220-topical-biological-agents-as-adjuncts-to-improve-wound-healing-in-chronic-diabetic-wounds-a-systematic-review-of-clinical-evidence-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":90,"URL":"https:\/\/doi.org\/10.7759\/cureus.27180","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,23]]}}}